a Wide, Phase 3 Study Testing of the Covid-19 vaccine, developed by AstraZeneca and the University of Oxford by the US Strazeneca, was conducted in the United States due to a suspected serious adverse reaction in a participant from the United Kingdom.
A spokesman for AstraZeneca, which is leading the race for the Covid-19 vaccine, said in a statement that the company’s “standard review process paused for vaccinations to allow review of safety data.”
It was not immediately clear who held the hearing, although it is possible that it was voluntarily placed by AstraZeneca and not ordered by any regulatory agency. The nature of the adverse reaction and when it occurred were also not immediately known, although participants are expected to recover, according to a person familiar with the matter.
Advertising
The spokesperson described the pause as “a routine action that occurs whenever there is a potentially unexplained illness in any test, when it is investigated, to ensure that we maintain the integrity of the tests.” The spokesman also said the company was “working to expedite the review of a single event to minimize any potential impact on the trial timeline.”
A person familiar with the development said the researchers were told the “plenty of caution” trial had been put on hold. Another person familiar with the matter, who spoke on condition of anonymity, said other AstraZeneca vaccine tests being tested were being affected – as well as clinical trials conducted by other vaccine manufacturers.
Advertising
Clinical holdings are not uncommon, and it is unclear how long AstraZeneca can last. But the company’s trial progress – and all the Covid-19 vaccines in development – is keeping an eye on the need for new ways to tackle the global epidemic. Is currently Nine vaccine candidates in the Phase 3 trial. AstraZeneca is the first phase 3 Kovid-19 vaccine trial to be made known.
Researchers conducting other trials are now looking for similar cases of adverse reactions by combing through the reviewed databases. A so-called Data and Safety Monitoring Board, another person said.
AstraZeneca only visited the U.S. in late August. Began its Phase 3 trial in. Government Registry ClinicalTrial.O.O.G. According to him, U.S. hearings are currently taking place at sites across the country, although some have not yet begun registering participants. The Phase 2/3 trial was previously launched in the UK, Brazil and South Africa.
There are a number of different reactions that may qualify as suspected severe adverse reactions, hospitalization, life-threatening illness and even symptoms necessary for death. It is also not clear in which clinical trial the adverse reaction occurred, although there is a clear possibility Phase 2/3 hearing is underway In the UK
While it is not yet clear how serious and rare an adverse event can be, finding out how quickly efficacy data from the UK trial will be available could have an impact. That is data U.S. It is considered integral to any bid to get emergency use approval for the vaccine from the Food and Drug Administration – and jeopardizes President Trump’s efforts to quickly protect the vaccine before the November election.
One phase 1/2 Study published in July Reportedly about 1000 participants have experienced this vaccine experienced side effects. All side effects, including fever, headache, muscle aches, and injection site reactions, were considered mild or moderate. All of the side effects reported also decreased during the study.
The vaccine – known as AZD1222 – uses the adenovirus that carries the gene for one of the proteins, SARS-CoV-2, the virus that causes Covid-19. Adenovirus is designed to induce the immune system to produce a protective response against SARS-2. The platform has not been used in approved vaccines, but has been tested in experimental vaccines against other viruses, including the Ebola virus.
U.S. The trial phase is aimed at registering approximately 1,000,000 participants at sites across the country. Published last week From national health organizations.
In response to that hold, the U.S. It was not immediately clear what steps were being taken at the study sites. Recruitment of new participants who are constantly participating in the clinical holding and existing ones have to be paused for dosing, unless it is considered in the interest of the safety of the participants to continue dosing.
In a statement from AstraZeneca, a company spokesman noted that “illnesses in the big test will happen by chance, but there must be an independent review to investigate this carefully.” The spokesman also said the company is “committed to the safety of our participants and the highest standards of conduct in our trials.”
